About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Clinicaltrials.gov identifier NCT03575351

Recruitment Status Recruiting

First Posted July 2, 2018

Last update posted August 31, 2020

Study Description

Brief summary:

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm A) or to receive JCAR017 (Arm B). All subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event. Subjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.

  • Condition or Disease:Lymphoma, Non-Hodgkin
  • Intervention/Treatment: Genetic: JCAR017
    Drug: Standard of Care
  • Phase: Phase 3
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 182 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
  • Actual Study Start Date: October 2018
  • Estimated Primary Completion Date: January 2024
  • Estimated Study Completion Date: January 2024
Arms and interventions
Arm Intervention/treatment
Active Comparator: Arm A - Standard of Care (SOC)
Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
Drug: Standard of Care
Standard of Care
Experimental: Arm B - JCAR017
Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
Genetic: JCAR017
JCAR017
Outcome Measures
  • Primary Outcome Measures: 1. Event-free survival (EFS) [ Time Frame: Approximately 3 years ]
    Time from randomization to death from any cause, progressive disease (PD), failure to achieve complete response (CR) or partial response (PR), or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first
  • Secondary Outcome Measures: 1. Complete response rate (CRR) [ Time Frame: Approximately 3 years ]
    Percentage of subjects achieving a complete response (CR)
  • 2. Progression-free survival (PFS) [ Time Frame: Approximately 3 years ]
    Time from randomization to PD or death from any cause, whichever occurs first
  • 3. Overall survival (OS) [ Time Frame: Approximately 4.5 years ]
    Time from randomization to time of death due to any cause
  • 4. Overall response rate (ORR) [ Time Frame: Approximately 3 years ]
    Percentage of subjects achieving an objective response of partial response (PR) or better according to the Lugano Classification as assessed by IRC review
  • 5. Duration of response (DOR) [ Time Frame: Approximately 3 years ]
    Time from first response to disease progression, start of new antineoplastic therapy due to efficacy concerns or death from any cause
  • 6. PFS on next line of treatment (PFS-2) [ Time Frame: Approximately 3 years ]
    Time from randomization to second objective disease progression or death from any cause, whichever is first.
  • 7. Adverse Events (AEs) [ Time Frame: Approximately 3 years ]
    Type, frequency and severity of adverse events (AEs), serious adverse events (SAE), and laboratory abnormalities (overall and in clinical, histological and molecular subgroups)
  • 8. HRQoL using European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC-QLQ-C30) [ Time Frame: Approximately 3 years ]
    European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire: The EORTC QLQ-C30 questionnaire will be used as a measure of health-related quality of life, fatigue, physical and cognitive functions.
  • 9. HRQoL parameters assessed by FACT-Lym "Additional concerns" subscale [ Time Frame: Approximately 3 years ]
    Functional Assessment of Cancer Therapy-Lymphoma "Additional concerns" subscale: Only the LYM subscale will be administered in this study. This scale addresses symptoms and functional limitations (15 item) that are important to lymphoma patients.
  • 10. Reasons for hospital resource utilization [ Time Frame: Approximately 3 years ]
    Will be assessed based on reasons for hospitalization
  • 11. Rate of hematopoietic stem cell transplant (HSCT) [ Time Frame: Approximately 3 years ]
    Rate of completion of HDCT and HSCT
  • 12. Frequency of hospital resource utilization [ Time Frame: Approximately 3 years ]
    Will be assessed based on frequency of hospitalizations calculated as, inpatient days, intensive care unit (ICU) days, outpatient visits days
  • 13. Hospital resource utilization (HRU) [ Time Frame: Approximately 3 years ]
    Will be assessed based on frequency of hospitalizations calculated as, inpatient days, intensive care unit (ICU) days, outpatient visits days and reasons for hospitalization
Eligibility Criteria
  • Ages Eligible for Study: 18 to 75 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Subject is ≥ 18 years and ≤ 75 years of age at the time of signing the informed
consent form (ICF).

2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

3. Histologically proven diffuse large B-cell lymphoma (DLBCL) NOS (de novo or
transformed indolent NHL), high grade B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangements with DLBCL histology (double/triple-hit lymphoma [DHL/THL]), primary
mediastinal (thymic) large B-cell lymphoma (PMBCL), T cell/histiocyte-rich large
B-cell lymphoma (THRBCL) or follicular lymphoma grade 3B. Enough tumor material must
be available for confirmation by central pathology.

4. Refractory or relapsed within 12 months from CD20 antibody and anthracycline
containing first line therapy.

5. [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) positive lesion at
screening. (Deauville score 4 or 5)

6. Adequate organ function

7. Participants must agree to use effective contraception

Exclusion Criteria:

1. Subjects not eligible for hematopoietic stem cell transplantation (HSCT).

2. Subjects planned to undergo allogeneic stem cell transplantation.

3. Subjects with, primary cutaneous large B-cell lymphoma, EBV (Epstein-Barr virus)
positive DLBCL, Burkitt lymphoma or transformation from chronic lymphocytic
leukemia/small lymphocytic lymphoma (Richter transformation).

4. Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the
subject has been free of the disease for ≥ 2 years with the exception of the following
noninvasive malignancies:

- Basal cell carcinoma of the skin

- Squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (T1a or T1b using the TNM
[tumor, nodes, metastasis] clinical staging system) or prostate cancer that is
curative.

- Other completely resected stage 1 solid tumor with low risk for recurrence

5. Treatment with any prior gene therapy product.

6. Subjects who have received previous CD19-targeted therapy.

7. Subjects with active hepatitis B, or active hepatitis C are excluded. Subjects with
negative polymerase chain reaction (PCR) assay for viral load for hepatitis B or C are
permitted. Subjects positive for hepatitis B surface antigen and/or anti-hepatitis B
core antibody with negative viral load are eligible and should be considered for
prophylactic antiviral therapy. Subjects with a history of or active human
immunodeficiency virus (HIV) are excluded.

8. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection
(including tuberculosis) despite appropriate antibiotics or other treatment.

9. Active autoimmune disease requiring immunosuppressive therapy.

10. History of any one of the following cardiovascular conditions within the past 6 months
prior to signing the ICF: Class III or IV heart failure as defined by the New York
Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction,
unstable angina, or other clinically significant cardiac disease.

11. History or presence of clinically relevant central nervous system (CNS) pathology

12. Pregnant or nursing (lactating) women.

Contacts and Locations
Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Show 53 Study Locations
Sponsors and Collaborators

Celgene

Investigators

Study Director: Alessandro Crotta, MD Celgene

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT03575351 History of Changes
  • Other Study ID Numbers: JCAR017-BCM-003, U1111-1213-1944, 2018-000929-32
  • First Posted: July 2, 2018 Key Record Dates
  • Last Update Posted: August 31, 2020
  • Last Verified: August 2020
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Safety
    JCAR017
    Liso-cel
    Relapsed
    Non-Hodgkin Lymphomas
    DLBCL
    Efficacy
    High-Risk
    Refractory
    B-cell NHL
  • Additional relevant MeSH terms: Lymphoma
    Lymphoma, Non-Hodgkin
    Lymphoma, B-Cell